Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. The company is headquartered in Emeryville, California and currently employs 405 full-time employees. The company went IPO on 2004-02-19. The firm has two commercial products: HEPLISAV-B vaccine (Hepatitis B Vaccine (Recombinant), Adjuvanted), and CpG 1018 adjuvant. The HEPLISAV-B vaccine is used for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose in-one-month adult hepatitis B vaccine. CpG 1018 adjuvant is used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. The firm is advancing a pipeline of differentiated product candidates that leverage its CpG 1018 adjuvant to develop improved vaccines in indications with unmet medical needs. Its pipeline programs include Shingles vaccine program (Z-1018) and Plague vaccine program. Z-1018 is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.

Industry: Pharmaceutical Preparations Peers: Akero Therapeutics, Inc. Celldex Therapeutics Inc BridgeBio Pharma Inc Veracyte Inc Catalyst Pharmaceuticals Inc Day One Biopharmaceuticals, Inc. Ligand Pharmaceuticals Inc Syndax Pharmaceuticals Inc SpringWorks Therapeutics, Inc.